10/8/2018 1 SCREENING, PREVENTION, TREATMENT Disclosure I have no financial disclosures. Focus of this presentation Background Etiology/History/Prevalence HPV Screening: History of cervical cancer screening Evolution of cervical screening Prevention: HPV Vaccine Treatment: Based on NCCN Guidelines Cervical Cancer Statistics 13,240 will be diagnosed with cervical cancer. 4,170 deaths from the disease will occur. America Cancer Society, 2018 Cervical Cancer Statistics 5-year survival rate for women with cervical cancer is 67.4% 10-year survival rate is 64% Broken down by stage early stage - 92% Regional spread - 57% Distant spread – 17% Cervical Cancer Statistics
12
Embed
Cervical cancer Screening - Clique Boutiqueadmin.abcsignup.com/.../21957/ECC-cervixcancer.pdfCervical Cancer Statistics 13,240 will be diagnosed with cervical cancer. 4,170 deaths
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
10/8/2018
1
SCREENING, PREVENTION, TREATMENT
Disclosure
I have no financial disclosures.
Focus of this presentation
Background
Etiology/History/Prevalence HPV
Screening:
History of cervical cancer screening
Evolution of cervical screening
Prevention: HPV Vaccine
Treatment:
Based on NCCN Guidelines
Cervical Cancer Statistics
13,240 will be diagnosed with cervical
cancer.
4,170 deaths from the disease will
occur.
America Cancer Society, 2018
Cervical Cancer Statistics
5-year survival rate for women with
cervical cancer is 67.4%
10-year survival rate is 64%
Broken down by stage
early stage - 92%
Regional spread - 57%
Distant spread – 17%
Cervical Cancer Statistics
10/8/2018
2
Cervical Cancer Statistics Cervical Cancer Statistics
P16 negative lesions may be lower-risk for progression
High p16 on TMA associated with LN metastasis and poorer survival outcomes
Ki-67 Expressed during cell proliferation
Not specific to cervical cancer
When used with p16 shows 94% sensitivity and 90% specificity in detecting CIN 2 or greater
C-myc Increased copy number is prognostic indicator of poor
likelihood of regression
Treatment for Cervical Cancer
Depends on the clinical stage
10/8/2018
7
Cervical Cancer Staging
Cervical Cancer Staging
Cervical Cancer Staging
Cervical Cancer Staging
Clinically staged Pelvic examination
Speculum, bimanual, and rectovaginal examination for palpation
and inspection of the primary tumor, uterus, vagina, and parametria
Examination for distant metastases
Palpation of groin and supraclavicular lymph nodes
Cervical Cancer Staging
10/8/2018
8
Pelvic examination Speculum, bimanual, and rectovaginal examination for palpation
and inspection of the primary tumor, uterus, vagina, and parametria
Examination for distant metastases Palpation of groin and supraclavicular lymph nodes
Cervical biopsy Colposcopy with directed cervical biopsy or cervical biopsy without
colposcopy if visible lesion
Conization/Endocervical curettage
Endoscopy Hysteroscopy, cystoscopy or proctoscopy
Imaging studies Intravenous pyelogram (IVP) – Evaluation for urinary tract
obstruction
Imaging with a plain chest radiograph and radiograph of the skeleton
Treatment
Stage
Desire for fertility
Tumor Volume
Medical co-morbidities
Known lymphatic spread
Age
Body habitus
Treatment based on stage
IA1 No LVSI – Cone vs extrafascial
hysterectomy
IA1 w LVSI, IB1, IB2, IIA – Radical
hysterectomy, pelvic lymphadenectomy
IB2, IIA, IIB, IIIA, IIIB, IVA – Concurrent
chemoradiation (consideration for
adjuvant chemotherapy)
IVB – Palliative chemotherapy, clinical
trial or best supportive care
Extrafascial vs Radical hysterectomy
Candidates for fertility preservation
Cervical Cancer
Options
Surgical ○ Radical trachelectomy,
lymphadenectomy
Vaginal
Laparoscopic or robotic
1http://seer.cancer.gov/csr/ 1975_2010/results_single/ sect_01_table.01.pdf, 2Sutton et al, Am. J. Obstet. Gynecol. 1992;166:50–53, 3Shimada et al, Gynecol Oncol. 2006;101(2):234-7. 4Lu et al, Gynecol Oncol. 2013;04:470.
Reconstruction of the uterine corpus to upper vagina after the cerclage is placed
The intent of the radical abdominal trachelectomy is to resect the cervix, upper 1–2 cm of the vagina, parametrium, and paracolpos in a similar manner to a type III radical abdominal hysterectomy but sparing the uterine corpus
Candidates for fertility preservation
Cervical Cancer
Radical abdominal trachelectomy— the cervical tissue and parametria are separated from the fundus
The uterine fundus is reattached to the vaginal apex
The reconstructed fundus with remaining blood supply from the intact utero-ovarian ligaments—uterine serosa without evidence of fundal ischemia
10/8/2018
9
Candidates for fertility preservation
Cervical Cancer
Obstetric outcomes >250 live births have been reported1
Plante et al, 20082, 20113
Survival outcomes
Recurrence
Mortality
1Lu et al, Gynecol Oncol. 2013;04:470. 2Plante et al, Gynecol Oncol. 2008;111:S105. 3Plante et al, Gynercol Oncol. 2011;121:290-7.
Plante 2008 N=256 pregnancies
Plante 2011 N=106 pregnancies
1st trimester loss 18% 20%
2nd trimester loss 8.6% 3%
3rd trimester delivery 62% 73%
Preterm delivery <37 weeks <32 weeks
28% 12%
18% 4%
Term delivery 40% 55%
Candidates for fertility preservation
Cervical Cancer
Oncologic outcomes
Plante et al, 20081, 20112
○ Risk Factors: 2008
Lesions larger than 2 cms (29 vs 1%)
Presence of LVSI (12 vs 2%)
○ Risk Factors: 2011
Lesions larger than 2 cms
1Plante et al, Gynecol Oncol. 2008;111:S105. 3Plante et al, Gynercol Oncol. 2011;121:290-7.
Plante 2008 N=603 patients (%)
Plante 2011 N=125 patients (%)
Recurrence rate 27 (4.5%) 6 (4.8%)
Death from disease (%)
15 (2.5%) 2 (1.6%)
Abandoned VRT 10-12% 4 (11%)
5 year PFS 96%
Radiation vs Radical Surgery
Equivalent cure rates for stage I and IIA
disease.
Case #1
33 yo G3P3
Post-coital bleeding
Exam showed 3cm friable cervical mass
with no parametrial or vaginal induration
Cervical biopsy – Grade 3 squamous
cell carcinoma
PET/CT Negative
Case #1
Treatment
Robotic-assisted radical hysterectomy with
bilateral salpingectomy and pelvic lymph
node dissection
Pathology
3.2 cm squamous cell carcinoma
No LVSI
Middle 1/3 invasion
Sedlis Criteria
Post surgery recurrence risk:
Intermediate risk: Sedlis: 30%
1. LVSI, outer 1/3, TS any
2. LVSI, middle1/3, TS >2cm
3. LVSI, Super 1/3, TS.5
4. No LVSI/deep/middle 1/3, TS >4
High Risk: 40%
Positive margins, nodes, parametrium
10/8/2018
10
Case #2
37 yo G2P2
Abnormal pap tests off and on since 20 yo
Cryotherapy 7 years ago
ASCUS pap 2013
Presented with abnormal bleeding and
discharge
Cervical mass seen on exam – Biopsy
proven squamous cell carcinoma
Treatment
Robotic assisted laparoscopic pelvic
lymph node debulking with para-aortic
sampling
Concurrent cisplatin and external beam
radiation therapy
High dose vaginal brachytherapy
Consideration for adjuvant
chemotherapy
Case #3
56 yo
Presented with abnormal bleeding
Last pap 1994
Clinical stage IIB with negative PET
Concurrent chemoradiation
Syed implant for brachytherapy (2/19/2015)
4/2015 No obvious parametrial induration
Case #3
Fell and hit abdomen 5/2015
Biopsied 6/2015
Consistent with metastatic squamous cancer
10/8/2018
11
Treatment for Recurrent
Cervical Cancer GOG 240
Paclitaxel/cisplatin ± bevacizumab
Paclitaxel/topotecan ± bevacizumab
Results
○ Paclitaxel/topotecan not superior or inferior to paclitaxel/cisplatin
○ Addition of bevacizumab shows improved PFS (8.2m vs 5.9m) and OS (17m vs 13.3m)
Lead to FDA approval of bevacizumab on August 14, 2014
Pembrolizumab (Keytruda)
June 12, 2018 - FDA approved
pembrolizumab (Keytruda, Merck and
Co. Inc.) for patients with recurrent or
metastatic cervical cancer with disease
progression on or after chemotherapy
whose tumors express PD-L1
Keynote 158
Single cohort 98 patients recurrent,
progressive cervical cancer
80% expressed PD-L1
ORR – 14.3% (CR – 2.6%/PR - 11.7%)
Median response duration not reached
91% had response ≥ 6 months
No responders in group without PD-L1
expression
On the Horizon
Advaxis
Engineered Listeria presenting HPV DNA as
foreign agent to stimulate immune system
PARP inhibitors
Cedirinib
potent inhibitor of vascular endothelial
growth factor (VEGF) receptor tyrosine
kinases
Quesitons?
References H. zur Hausen, L. Gissmann, W. Steiner, W. Dippold and I. Dreger. Human papilloma viruses and cancer. Bibl Haematol. 1975 569-71.
C. P. Crum, M. Mitao, R. U. Levine and S. Silverstein. Cervical papillomaviruses segregate within morphologically distinct precancerous lesions. J Virol. 1985 54:675-81.
S. Syrjanen, K. Syrjanen, R. Mantyjarvi, S. Parkkinen, M. Vayrynen, S. Saarikoski and O. Castren. Human papillomavirus (HPV) DNA sequences demonstrated by in situ DNA hybridization in serial paraffin-embedded cervical biopsies. Arch Gynecol. 1986 239:39-48.
K. Syrjanen, S. Parkkinen, R. Mantyjarvi, M. Vayrynen, S. Syrjanen, H. Holopainen, S. Saarikoski and O. Castren. Human papillomavirus (HPV) type as an important determinant of the natural history of HPV infections in uterine cervix. Eur J Epidemiol. 1985 1:180-7.
K. Syrjanen, R. Mantyjarvi, M. Vayrynen, S. Syrjanen, S. Parkkinen, M. Yliskoski, S. Saarikoski and O. Castren. Evolution of human papillomavirus infections in the uterine cervix during a long-term prospective follow-up. Appl Pathol. 1987 5:121-35.
L. Koutsky. Epidemiology of genital human papillomavirus infection. Am J Med. 1997 102:3-8.
R. W.S. Crusade: The Official History of the American Cancer Society. 1987 76-93
Vaccination coverage among adolescents aged 13-17 years – United States, 2007. Morb Mort Wkly Rep 2008;57:1100-3
Saraiya M, Ahmed F, Krishnan S, Richards TB, Unger ER, Lawson HW. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol. 2007;109:360-70.
Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin. 1999;49:8-31,
Wingo PA, Cardinez CJ, Landis SH, et al. Long-term trends in cancer mortality in the United States, 1930-1998. Cancer. 2003;97:3133-275.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
Report WH. Changing History. Statistical Annex. . World Health Organization; 2004.
Group UCSW. United States Cancer Statistics 2004, Incidence and Mortality. Atlanta, GA: Department of Health and Human Services, Center for Disease Control and Prevention, and National Cancer Institute. 2007.
Health NIo. Cervical Cancer. . NIH Consensus Statment; 1996:1-38.
Revzina NV, Diclemente RJ. Prevalence and incidence of human papillomavirus infection in women in the USA: a systematic review. Int J STD AIDS. 2005;16:528-37.
Weinstock H, Berman S, Cates W, Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004;36:6-10.
Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev. 2001;10:101-6.
Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med. 2003;127:930-4.
Greer CE, Wheeler CM, Ladner MB, et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058-63.
Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
Castellsague X, Diaz M, de Sanjose S, et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006;98:303-15.
10/8/2018
12
References Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review
and meta-analysis. Obstet Gynecol. 2008;111:167-77.
Tidy JA, Mason WP, Farrell PJ. A new and sensitive method of screening for human papillomavirus infection. Obstet Gynecol. 1989;74:410-4.
Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol. 2000;44:726-42.
Wright TC, Jr., Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological
abnormalities. Jama. 2002;287:2120-9.
Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues
in cancer screening. CA Cancer J Clin. 2009;59:27-41.
Screening for cervical cancer: recommendations and rationale. Am J Nurs. 2003;103:101-2, 105-6, 108-9.
Cox JT. Clinical role of HPV testing. Obstet Gynecol Clin North Am. 1996;23:811-51.
Cuzick J, Szarewski A, Mesher D, et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-Results from
the Hammersmith study. Int J Cancer. 2008;122:2294-300.
Bulkmans NW, Rozendaal L, Voorhorst FJ, Snijders PJ, Meijer CJ. Long-term protective effect of high-risk human papillomavirus testing in population-
based cervical screening. Br J Cancer. 2005;92:1800-2.
Wright TC, Jr., Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect
cervical cancer. Jama. 2000;283:81-6.
Fambrini M, Penna C, Pieralli A, et al. PCR detection rates of high risk human papillomavirus DNA in paired self-collected urine and cervical scrapes
after laser CO2 conization for high-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2008;109:59-64. Epub 2008 Feb 5.
Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360:1385-94.
Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111:145-53.
Khleif SN, DeGregori J, Yee CL, et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor
activity. Proc Natl Acad Sci U S A. 1996;93:4350-4.
Klaes R, Benner A, Friedrich T, et al. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraepithelial
neoplasia. Am J Surg Pathol. 2002;26:1389-99.
Negri G, Vittadello F, Romano F, et al. p16INK4a expression and progression risk of low-grade intraepithelial neoplasia of the cervix uteri. Virchows
Arch. 2004;445:616-20. Epub 2004 Oct 9.
Wang JL, Zheng BY, Li XD, Angstrom T, Lindstrom MS, Wallin KL. Predictive significance of the alterations of p16INK4A, p14ARF, p53, and proliferating
cell nuclear antigen expression in the progression of cervical cancer. Clin Cancer Res. 2004;10:2407-14.
Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell
proliferation. Int J Cancer. 1983;31:13-20.
Van Niekerk D, Guillaud M, Matisic J, et al. p16 and MIB1 improve the sensitivity and specificity of the diagnosis of high grade squamous intraepithelial
lesions: methodological issues in a report of 447 biopsies with consensus diagnosis and HPV HCII testing. Gynecol Oncol. 2007;107:S233-40. Epub